# bestpeptide.org # Five Peptides, Graded by What Their Evidence Can Actually Support > Best Peptide — Research Peptide Fundamentals research peptides, graded by evidence — An independent literature desk grading Research Peptide Fundamentals research peptides — CJC-1295, ipamorelin, KPV, retatrutide, and semaglutide — by what their evidence actually supports. A digest, not a vendor or clinic. **RESEARCH PEPTIDE FUNDAMENTALS / EVIDENCE DESK** A skeptic's tour of the research-peptide landscape — a GHRH analog, a ghrelin-receptor secretagogue, an anti-inflammatory tripeptide, an investigational triple agonist, and one approved GLP-1 drug — read against the strength, not the volume, of what has actually been published. ### [CJC-1295](/cjc-1295) ![CJC-1295 research illustration](images/cjc-1295.webp) A long-acting growth-hormone-releasing-hormone analog. The human evidence is real but thin: a handful of small pharmacokinetic studies from the 2000s, no controlled efficacy trial, and a discontinued development program. ### [Ipamorelin](/ipamorelin) ![Ipamorelin research illustration](images/ipamorelin.webp) A selective ghrelin-receptor secretagogue prized for a clean side-effect profile. Its only human randomized trial missed its primary endpoint — a fact its marketing rarely mentions. ### [KPV](/kpv) ![KPV research illustration](images/kpv.webp) An anti-inflammatory tripeptide with a genuinely interesting rodent-colitis literature and precisely zero published human trials — the furthest from clinical evidence of anything on this desk. ### [Retatrutide](/retatrutide) ![Retatrutide research illustration](images/retatrutide.webp) A triple GIP/GLP-1/glucagon agonist posting the largest Phase 2 weight-loss figures on record. Investigational, unapproved, and still one clinical phase short of the evidence its reputation implies. ### [Semaglutide](/semaglutide) ![Semaglutide research illustration](images/semaglutide.webp) The one compound here with a large, approved, outcome-trial-backed evidence base — the benchmark the other four are implicitly measured against. ## The short version Best Peptide is a literature desk for five research peptides that get discussed together but sit at very different points on the evidence ladder: CJC-1295, ipamorelin, KPV, retatrutide, and semaglutide. A *research peptide* is a short chain of amino acids — the same building blocks as proteins, just much smaller — that is studied for a specific biological effect, usually by mimicking or blocking a natural hormone or signal. What sets this site apart is what it does **first**: before describing what a peptide might do, it states how solid the evidence is that it does it. That means naming when a finding comes from a single small human trial, a rat or mouse study, or nothing more than a community forum post. Two of the five compounds here (semaglutide, and to a lesser degree retatrutide) are backed by real clinical trials. The other three (CJC-1295, ipamorelin, KPV) rest on much thinner human data, and marketing for all five routinely outruns what has actually been shown. This page, and every page linked from it, tries to keep the compound and the confidence clearly separated. ## Grading the evidence, not just describing it The organizing idea on this desk is to line up **the best-evidenced research peptides across categories** — growth-hormone-axis peptides, an anti-inflammatory tripeptide, and a metabolic incretin agonist — and be explicit about where each one's evidence actually stops. - [**Semaglutide**](/semaglutide) sits furthest up the ladder: a GLP-1 receptor agonist with multiple large, randomized, outcome-driven trials and FDA approval across several indications [21][23][24]. - [**Retatrutide**](/retatrutide) is close behind mechanistically but earlier in development: Phase 2 data only, with the largest weight-loss figures reported to date for this drug class, and no Phase 3 readout yet [19][20]. - [**Ipamorelin**](/ipamorelin) has real human pharmacokinetic data and a single randomized controlled trial — one that missed its primary efficacy endpoint [8][9]. - [**CJC-1295**](/cjc-1295) has real human GH/IGF-1 pharmacology data from small studies, but no controlled efficacy trial of any kind [4][5]. - [**KPV**](/kpv) has a substantial and reasonably consistent rodent literature and, as far as the published record shows, no human trial at all [11][13][14]. That ordering is not a judgment about which compound is scientifically more interesting — KPV's mechanism is arguably the cleanest story of the five. It is a statement about what a reader is actually entitled to conclude from what has been published, which is the only question this desk tries to answer. ## What are research peptides? Peptides are chains of amino acids shorter than a full protein — as few as three residues (KPV) or as many as thirty-nine (retatrutide). Because many peptide hormones and signaling molecules occur naturally in the body — growth-hormone-releasing hormone, ghrelin, alpha-melanocyte-stimulating hormone, glucagon-like peptide-1 — synthetic analogs can be built to mimic, extend, or block those signals with more precision or a longer duration of action than the native molecule allows. 'Research peptide' is industry shorthand for a peptide sold by chemical suppliers explicitly for laboratory research use, not as an approved drug or dietary supplement. Semaglutide is the exception on this desk: it graduated from that category into full FDA approval years ago. Retatrutide is mid-transition, in Phase 3 trials but still investigational. CJC-1295, ipamorelin, and KPV remain, by regulatory status, research chemicals — sold and marketed for laboratory use, with no approved human indication anywhere. That status is not a technicality. It means no agency has verified the identity, purity, dose-response relationship, or long-term safety of what is being sold, and this site treats that fact as load-bearing rather than a footnote. ## How this desk reads a claim Three habits run through every page here. First, findings are reported in the species and population actually studied — a rat-bone-growth result is labeled as a rat result, not silently generalized to people. Second, a single study is called a single study; this desk does not treat one eleven-person pharmacokinetic trial the same as a multi-thousand-participant randomized outcome trial, even when both are 'published research.' Third, where a compound has real community-reported benefits or side effects but no controlled human trial to check them against, that gap is stated plainly rather than papered over with mechanism. None of this is medical advice, none of it recommends a dose for any person, and none of it should be read as encouragement to buy or use any of these five compounds outside a legitimate research or clinical setting. --- A skeptic's literature desk — we say plainly when the evidence behind a claim is a single small trial, a rat model, or nothing but community anecdote, before we say anything else. --- # CJC-1295: A Long-Acting GHRH Analog With Real Pharmacology and No Efficacy Trial > CJC-1295: Research Overview — Best Peptide — A skeptic's literature summary of CJC-1295, a long-acting GHRH analog. Covers the DAC/no-DAC mechanism, the small human pharmacokinetic evidence base, and cited safety cautions — no dosing advice. **01 / RESEARCH PEPTIDE FUNDAMENTALS** Small human studies confirm it raises growth hormone and IGF-1 for days at a time. What those studies do not confirm is whether that translates into any of the outcomes it is marketed for. ## The short version CJC-1295 is a lab-made version of growth-hormone-releasing hormone (GHRH), the natural signal that tells the pituitary gland to release growth hormone. Four small chemical changes make it resist breakdown in the body, and in its long-acting 'DAC' form, it also attaches to a blood protein called albumin, which lets a single dose keep growth hormone and a related hormone, IGF-1, elevated for days rather than minutes. What is actually known about it in people comes from a handful of small studies from the mid-2000s — fewer than 40 total volunteers across the published human research — showing that it does raise growth hormone and IGF-1 as designed. What is not known: whether raising those hormones this way produces any of the muscle, fat-loss, sleep, or anti-aging outcomes commonly claimed for it, because no controlled human trial has tested any of them. CJC-1295 is not approved for human use anywhere, and it is sold only as a research chemical. ## What it is CJC-1295 is a synthetic analog of the first 29 amino acids of human growth-hormone-releasing hormone, hGRF(1-29), carrying four substitutions — D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27 — that stabilize its alpha-helical structure and block the enzymatic cleavage, deamidation, and oxidation that destroy native GHRH within minutes. Two distinct forms circulate under the CJC-1295 name and are frequently confused with each other. The 'DAC' (Drug Affinity Complex) form adds a maleimidopropionyl linker at the C-terminus that forms a covalent bond with a free thiol on circulating serum albumin — effectively hitching the peptide to a blood protein with a multi-day lifespan of its own. The 'no-DAC' form (sometimes sold as 'Modified GRF 1-29') keeps the four stabilizing substitutions but skips the albumin-binding chemistry, and is correspondingly short-acting — active for minutes to hours rather than days. Because these two forms behave so differently in the body, knowing which one is actually in a vial matters more than most marketing acknowledges. ## How it works CJC-1295 binds the growth-hormone-releasing hormone receptor (GHRHR) on somatotroph cells in the anterior pituitary, activating a Gs-protein/cAMP/PKA signaling cascade that stimulates both the synthesis and the pulsatile release of growth hormone. Growth hormone released this way then acts on the liver to raise circulating IGF-1, the hormone most directly responsible for GH's anabolic effects on muscle and connective tissue. A notable and somewhat reassuring detail from the human data: continuous GHRH-receptor stimulation with CJC-1295 does not appear to flatten the body's normal pulsatile pattern of GH release into one long plateau. A human dosing study found the frequency and magnitude of GH pulses were preserved even under sustained CJC-1295 exposure [5] — the drug appears to raise the baseline and amplify the pulses rather than replacing pulsatile secretion with constant secretion. Whether that distinction matters clinically is not established; it is simply what the pharmacology shows so far. ## What the research shows *Framing review.* A 2025 review in a major endocrinology journal synthesizes the pharmacology of GHRH and its synthetic analogs as a class — including CJC-1295, sermorelin, and tesamorelin — describing receptor signaling and the general therapeutic landscape. It is a review, not new primary data, and should be read as context rather than fresh evidence for CJC-1295 specifically [1]. *Analytical identification, not efficacy.* A 2010 study used high-resolution mass spectrometry to confirm that a seized, unlabeled 'GHRH' preparation in an anti-doping context actually contained CJC-1295 [2]. This is chemistry, not pharmacology — it establishes that the compound circulates in the black market under vague labels, and nothing about whether it works. *Serum proteome study, n=11.* In eleven healthy young men, CJC-1295 shifted several serum proteins, and one signal tracked linearly with IGF-1 levels [3]. A genuinely small study exploring candidate biomarkers, not a clinical outcome trial. *The core pharmacokinetic data.* In healthy adults aged 21 to 61, single subcutaneous doses of 30 or 60 micrograms per kilogram produced dose-dependent 2- to 10-fold increases in mean plasma growth hormone lasting six days or more, and 1.5- to 3-fold increases in IGF-1 lasting nine to eleven days. After repeated dosing, IGF-1 stayed above baseline for up to 28 days, and the estimated half-life of CJC-1295 itself was 5.8 to 8.1 days [4]. This is the single most-cited human dataset for the compound — a dose-response pharmacokinetic study, not an efficacy trial for any downstream outcome. *Pulsatility preserved.* A single 60 or 90 microgram/kg dose in healthy men aged 20 to 40 raised trough GH roughly 7.5-fold and both mean GH and IGF-1 substantially one week later, while leaving the underlying pattern of pulsatile GH secretion intact [5]. Read together, [4] and [5] are the entirety of the controlled human pharmacology base for CJC-1295 — real, reproducible, and narrow in scope. ## Reported effects, cautions & safety The claims made for CJC-1295 in research-use communities go well beyond anything the studies above measured. What follows is **anecdotal, not clinical evidence** — self-reported experience from online forums and consumer guides, none of it collected under controlled conditions or attached to a verified dose. The most consistently reported benefit is deeper, more restful sleep, often described as the first effect noticed. Faster training recovery, gradual fat loss (usually reported after three to six weeks, alongside diet and exercise), a leaner appearance, modestly increased daytime energy, and sharper focus follow in roughly that order of frequency. On the adverse side, water retention and facial or hand puffiness are the most common complaint, attributed by the community to the long-acting DAC form specifically. Tingling or numbness in the hands (likened to mild carpal tunnel), minor injection-site irritation, flushing or a brief head-rush after injecting, fatigue, headache, and — mainly when CJC-1295 is stacked with ipamorelin — increased appetite round out the more frequent reports. A smaller number of accounts describe elevated blood sugar with sustained use. The cited safety concerns are mechanistic, not drawn from any dedicated CJC-1295 safety trial, because none exists. CJC-1295 elevates IGF-1, a mitogen linked in population studies to a modestly increased cancer risk, giving anyone with a personal or family history of cancer a real mechanism-based reason for caution. Growth hormone's sodium- and water-retaining action gives the reported bloating and nerve-compression effects a plausible physiological basis, and its glucose-sparing action is a legitimate concern for anyone with diabetes or insulin resistance [4]. A current pharmacology review flags immunogenicity considerations for long-acting, albumin-binding GHRH analogs like the DAC form [1], and the original long-acting CJC-1295 DAC development program was discontinued, with a patient death during that era frequently cited alongside the halted trial — though the public record does not establish that CJC-1295 caused it. CJC-1295 is prohibited in sport at all times and is not approved for human use by any regulator. ## Where it fits in the evidence hierarchy Among the five compounds on this desk, CJC-1295 occupies an odd middle position: its core human pharmacology — that it reliably raises GH and IGF-1 for days at a time [4][5] — is more solidly established in people than KPV's mechanism (rodent-only) or, arguably, than ipamorelin's clinical case (a failed trial [8]). But CJC-1295 has never been tested for any actual outcome in a controlled human trial — no muscle, fat-loss, sleep, or anti-aging endpoint has been measured against placebo in people. [Semaglutide](/semaglutide) and, to a lesser extent, [retatrutide](/retatrutide) have exactly that kind of outcome data; CJC-1295 does not. The honest summary is that CJC-1295's pharmacology is well characterized and its efficacy for any of its marketed uses is simply untested. See the [comparison page](/compare) for how all five stack up side by side. ![CJC-1295 research illustration — abstract growth-hormone axis motif in teal noir](/images/cjc-1295.webp) --- A skeptic's literature desk — we say plainly when the evidence behind a claim is a single small trial, a rat model, or nothing but community anecdote, before we say anything else. --- # Ipamorelin: A Clean Mechanism, One Human Trial, and a Missed Endpoint > Ipamorelin: Research Overview — Best Peptide — A skeptic's literature summary of ipamorelin, a selective ghrelin-receptor growth-hormone secretagogue. Covers its founding pharmacology, its one human RCT (which missed its endpoint), and cited safety cautions. **02 / RESEARCH PEPTIDE FUNDAMENTALS** Ipamorelin's signature feature — releasing growth hormone without also raising cortisol or prolactin — is well established. Its actual clinical efficacy is not: the only randomized trial run in people did not meet its primary goal. ## The short version Ipamorelin is a five-amino-acid peptide that switches on the ghrelin receptor (formally, GHS-R1a) on the pituitary gland, triggering a burst of growth-hormone release. Its defining feature, established in the founding animal studies, is that it does this selectively — unlike older growth-hormone peptides, it does not meaningfully raise stress or reproductive hormones like cortisol or prolactin along with it. That selectivity is genuinely well documented. What is not well documented is whether ipamorelin actually helps with anything in people. The only published randomized controlled trial of ipamorelin in humans — testing it for faster gut recovery after bowel surgery — did not meet its primary endpoint. Beyond that single study and one small pharmacokinetic trial, the human evidence for ipamorelin is thin, and no long-term human safety data exist for the doses and durations used in research-community protocols. Ipamorelin is not approved for human use anywhere. ## What it is Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 — an unusual amino acid (alpha-aminoisobutyric acid) at position one, plus two D-amino acids that confer resistance to enzymatic breakdown. It was derived from an earlier compound, GHRP-1, by removing a central two-amino-acid segment, and it acts as a selective agonist at the ghrelin receptor, GHS-R1a. Because it targets a different receptor than growth-hormone-releasing hormone (the receptor CJC-1295 acts on), ipamorelin is frequently paired with GHRH analogs in research protocols on the theory that stimulating both pathways at once produces a larger GH pulse than either alone. That combination theory rests on separate single-agent pharmacology for each compound; no published trial has tested the combination itself for any outcome. ## How it works Ipamorelin binds GHS-R1a on pituitary somatotrophs, triggering a discrete pulse of growth-hormone release through a mechanism distinct from and complementary to the GHRH-receptor pathway. Its defining pharmacological feature, established in the compound's original characterization, is that it does this without meaningfully raising ACTH, cortisol, or prolactin, even at doses far above the amount needed to trigger GH release — a selectivity problem that plagued earlier growth-hormone-releasing peptides like GHRP-6 and GHRP-2. Beyond the pituitary, GHS-R1a is also expressed on gut and vagal neurons (relevant to gastric motility, which is why it was tested for postoperative bowel recovery) and, in animal tissue, on pancreatic islet cells, where ipamorelin has shown a GH-independent effect on insulin release. Because GHS-R1a is the ghrelin receptor — ghrelin being the primary hunger hormone — ipamorelin also carries a class-level appetite-stimulating signal, though this appears less pronounced with ipamorelin specifically than with older, less selective compounds in the same family. ## What the research shows *Human efficacy trial — missed its endpoint.* The only published Phase 2 randomized controlled trial of ipamorelin enrolled 114 adults undergoing bowel resection, giving 0.03 mg/kg intravenously twice daily for up to seven days. Median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo — numerically faster, but not statistically significant (p=0.15) [8]. Treatment-emergent adverse events were reported in 87.5% of the ipamorelin group versus 94.8% of placebo — no worse than placebo in this short perioperative window, but this is the sole efficacy data point ipamorelin has ever generated in people, and it did not clear its own bar. *Human pharmacokinetics.* In eight healthy male volunteers per dose level, five short intravenous infusions ranging from roughly 4 to 140 nmol/kg produced dose-proportional pharmacokinetics, a terminal half-life of about two hours, and a single discrete GH pulse peaking around 40 minutes after dosing [9]. This is the foundational human dosing data, and it comes from acute single-dose intravenous administration — a very different route and timescale from the subcutaneous, repeated, self-administered protocols common in research-use communities. *Animal efficacy signal.* In a 2024 ferret study, ipamorelin reduced chemotherapy-associated (cisplatin-induced) weight loss by roughly 24% during the delayed phase, though it had no effect on nausea or vomiting in the same model [6] — the most recent published in vivo data, and it is in ferrets, not people. *Bone growth in rats.* Subcutaneous ipamorelin dose-dependently increased longitudinal bone growth rate in adult female rats, from 42 to as much as 52 micrometers per day at the highest dose, without changing total IGF-1 or bone-turnover markers [10] — a rodent skeletal finding, notable mainly because the effect appeared partly independent of circulating IGF-1. *A class-level safety signal, not an ipamorelin-specific one.* A 28-day preclinical safety study of a different ghrelin-receptor agonist (not ipamorelin) found dose-dependent myocardial degeneration and necrosis in rats, detectable on histopathology and by an elevated cardiac biomarker [7]. This does not show that ipamorelin causes heart damage — a different molecule was tested — but it establishes that chronic dosing at this receptor carries a documented cardiotoxicity signal in at least one related compound, which is why long-term ipamorelin safety remains an open question rather than a settled one. ## Reported effects, cautions & safety As with CJC-1295, what follows is **anecdotal, not clinical evidence** — self-reported experience from peptide-user forums, not data from the controlled trial described above. Deeper, more restorative sleep is the most consistently reported benefit, often noticed within one to two weeks, sometimes preceded by vivid dreams that settle down with continued use. Faster physical recovery and reduced training soreness are frequently described, as is a gradual shift toward leaner body composition over five to twelve weeks — usually qualified as dependent on concurrent diet and training. On the adverse side, facial flushing or a brief warm head-rush shortly after injection is widely reported, often compared to a niacin flush. Tingling or numbness in the hands and feet, mild water retention (described as milder than with older GHRP compounds), and increased hunger after injection — consistent with the ghrelin-receptor mechanism — are also commonly described, along with occasional dizziness, injection-site irritation, and a sense that sleep-related effects fade after three to four months, which the community addresses by cycling on and off. The cautions the literature actually supports are mechanistic rather than drawn from any long-duration ipamorelin safety trial. Growth hormone elevation raises a theoretical, class-level concern for anyone with an active or recent malignancy, since IGF-1 is a well-characterized mitogen — though no ipamorelin-specific tumor-promotion data exist in any species [10]. The ghrelin-receptor mechanism carries a documented cardiovascular caution: the related-compound cardiotoxicity finding [7] means chronic dosing at this receptor is not cleared for cardiovascular safety, and anyone with existing heart disease or significant fluid retention should weigh that unresolved signal. Growth hormone's glucose-sparing action, combined with ipamorelin's direct effect on pancreatic insulin release in animal tissue, makes the net effect on blood sugar difficult to predict in anyone with diabetes. Beyond the missed-endpoint trial [8] and the acute pharmacokinetic study [9], no controlled human safety data exist for the repeated, self-administered protocols used in research communities, and research-grade ipamorelin from unregulated suppliers carries no pharmaceutical quality assurance. ## Where it fits in the evidence hierarchy Ipamorelin's mechanism — selective GH release without the cortisol and prolactin baggage of older GHRPs — is arguably the most cleanly characterized pharmacology story of the five compounds on this desk. But mechanism is not efficacy, and ipamorelin is the only compound here whose sole human efficacy trial actually failed to meet its own primary endpoint [8]. That puts it in a strange position relative to [CJC-1295](/cjc-1295), which has no efficacy trial at all (so nothing has failed, but nothing has succeeded either), and a very different position from [semaglutide](/semaglutide), whose efficacy case rests on repeated, large, positive outcome trials [21][23][24]. A rigorous reading of ipamorelin's evidence base is: real, selective GH-releasing pharmacology, and an actual clinical test that did not clear its bar. See the [comparison page](/compare) for how all five compare. ![Ipamorelin research illustration — abstract ghrelin-receptor motif in teal noir](/images/ipamorelin.webp) --- A skeptic's literature desk — we say plainly when the evidence behind a claim is a single small trial, a rat model, or nothing but community anecdote, before we say anything else. --- # KPV: The Cleanest Rodent Data on This Desk, and No Human Trial at All > KPV: Research Overview — Best Peptide — A skeptic's literature summary of KPV, an anti-inflammatory melanocortin-derived tripeptide. Covers the PepT1-mediated mechanism, the mouse-colitis evidence base, and the complete absence of published human trials. **03 / RESEARCH PEPTIDE FUNDAMENTALS** KPV's anti-inflammatory mechanism is unusually well replicated across mouse colitis models. What has never happened, in any published study, is testing it in a person. ## The short version KPV is a tiny peptide — just three amino acids, lysine-proline-valine — that corresponds to the tail end of a natural hormone called alpha-MSH. In mice, it consistently calms intestinal inflammation in colitis models without producing the skin-darkening effect of its parent hormone, and it gets into gut-lining cells through a specific transporter that is turned up during inflammation, which is a genuinely elegant piece of biology. The honest caveat, and the reason this page reads differently from most KPV marketing, is that every study behind that picture is in vitro or in an animal — chiefly mice. As of this writing, no published human clinical trial of KPV exists. That means there is no human dose, no human safety profile, and no human efficacy data to report — only a research chemical with a promising rodent story and an entirely open question about whether any of it translates to people. ## What it is KPV is the linear tripeptide lysine-proline-valine (Lys-Pro-Val), corresponding to residues 11 through 13 — the C-terminal end — of alpha-melanocyte-stimulating hormone (alpha-MSH). It is one of the smallest bioactive peptides in the research literature, small enough that its behavior in the body is governed less by receptor pharmacology in the conventional sense and more by how efficiently it can be absorbed and delivered intact before peptidases break it down. That fragility is the central practical problem in the KPV literature. Free KPV is readily degraded by peptidases, and a meaningful share of the recent published research is not about KPV's biological effect at all, but about formulation engineering — nanoparticles, hydrogels, and targeted delivery systems designed to keep it intact long enough to reach inflamed tissue [11][12]. ## How it works KPV retains the anti-inflammatory activity of its parent hormone, alpha-MSH, while lacking alpha-MSH's pigmentary (melanogenic) effect — the two functions of the parent molecule are pharmacologically separable, and KPV isolates the anti-inflammatory half. Mechanistically, it suppresses NF-kB and MAP-kinase inflammatory signaling and reduces the production of pro-inflammatory cytokines such as IL-1beta and TNF-alpha [13]. A distinctive delivery mechanism sets KPV apart from most peptides on this desk: it is taken up directly into intestinal epithelial cells by the di/tripeptide transporter PepT1 (gene name SLC15A1), which is notably upregulated in inflamed gut tissue [13]. That means KPV's effect is, in principle, self-targeting — it is absorbed more where inflammation is worse — which is the biological rationale for the newer nanoparticle- and hydrogel-based oral delivery systems designed to exploit that same transporter [11][12]. ## What the research shows *PepT1-targeted nanodrug, mouse colitis.* A 2024 study co-assembled KPV with the immunosuppressant FK506 into PepT1-targeted nanoparticles and found the combination improved outcomes in both acute and chronic DSS-induced colitis in mice, restoring tight-junction proteins and lowering inflammatory cytokines beyond either drug given alone [11]. This is combination-formulation research in mice, not a KPV monotherapy human result. *Oral nanoparticle delivery, mouse colitis.* Hyaluronic-acid-functionalized nanoparticles carrying KPV, embedded in a chitosan/alginate hydrogel, delivered the peptide to inflamed colon tissue and reduced colitis severity in mice more effectively than non-targeted formulations, with stronger prevention of mucosal damage and lower TNF-alpha [12]. Again, a mouse model, and delivery-system-focused. *Foundational mechanism paper.* KPV enters human intestinal epithelial cells (in cell-culture lines) via PepT1, and nanomolar concentrations inhibit NF-kB and MAP-kinase activation and cytokine secretion in both epithelial and immune cells in vitro; the same paper found oral KPV reduced colitis severity in two different mouse models [13]. This is the mechanistic backbone the rest of the KPV literature builds on. *Independent colitis replication.* A separate study found KPV reduced colonic inflammation in mice across two different colitis models, with earlier recovery, lower markers of tissue neutrophil activity, and reduced inflammatory infiltrate — and, notably, the effect held even in mice genetically lacking the melanocortin-1 receptor, indicating the anti-inflammatory action does not require that specific receptor [14]. This cross-model replication is one of the stronger pieces of evidence in the KPV file, and it is still entirely a mouse finding. *Review context.* A comprehensive 2008 review situates KPV within a family of alpha-MSH-derived tripeptides showing anti-inflammatory activity across many animal models of disease, explicitly framing KPV as an anti-inflammatory alternative to alpha-MSH because it keeps the anti-inflammatory action while losing the pigmentary one [15]. It is a review, synthesizing findings like [11] through [14], not a new primary result. ## Reported effects, cautions & safety This site does not fabricate community-reported anecdotes where none have been documented, and — unlike CJC-1295, ipamorelin, semaglutide, and retatrutide — no meaningful, verifiable body of KPV-specific real-world-use reports exists in the sources this desk draws on. That absence is itself informative: KPV has a far smaller and more recent research-community footprint than the growth-hormone-axis or metabolic peptides on this desk, and this page will not invent a folklore of reported effects to fill the gap. What can be said, honestly, comes from the published record itself rather than from anecdote. No published human clinical trial of KPV exists, so there is no human dosing regimen, no documented human side-effect profile, and no human safety data of any kind — a materially different situation from ipamorelin or CJC-1295, both of which at least have small human pharmacokinetic studies behind them [4][5][9]. Free KPV is a small, peptidase-labile molecule with no validated human pharmacokinetics; the active formulation research [11][12] exists precisely because the free peptide does not reliably survive long enough in the body to be useful without protection, which is itself a caution about any research-grade KPV product that does not address that stability problem. KPV is derived from alpha-MSH, and while its defining feature in the literature is that it lacks alpha-MSH's pigmentary action, it should not be conflated with melanocortin agonists marketed for tanning — the KPV research base is specifically about anti-inflammatory action, not pigmentation. Secondary web sources for KPV frequently carry citation errors, wrong identifiers copied from aggregator to aggregator; every identifier in this desk's KPV file was independently re-verified against the primary literature rather than copied secondhand. KPV is sold only as a research chemical for laboratory use and has no approved drug or dietary-supplement status anywhere. ## Where it fits in the evidence hierarchy KPV is the clearest illustration on this desk of a gap between mechanistic elegance and clinical evidence. Its core biology — a natural transporter that concentrates it where inflammation is worst, a cytokine-suppressing effect replicated across independent studies and multiple mouse colitis models [11][13][14] — is a genuinely tidy story. But it is a rodent and in-vitro story from beginning to end. [CJC-1295](/cjc-1295) and [ipamorelin](/ipamorelin) at least have small human pharmacokinetic trials; [semaglutide](/semaglutide) and [retatrutide](/retatrutide) have large human efficacy trials. KPV has neither — which does not mean the mechanism is wrong, only that no one has yet tested whether it holds up in a person. See the [comparison page](/compare) for the full evidence-maturity picture. ![KPV research illustration — abstract anti-inflammatory tripeptide motif in teal noir](/images/kpv.webp) --- A skeptic's literature desk — we say plainly when the evidence behind a claim is a single small trial, a rat model, or nothing but community anecdote, before we say anything else. --- # Retatrutide: The Best Phase 2 Numbers in the Class, Still Missing Phase 3 > Retatrutide: Research Overview — Best Peptide — A skeptic's literature summary of retatrutide (LY3437943), an investigational GIP/GLP-1/glucagon triple agonist. Covers the mechanism, the Phase 2 trial data, and why the evidence is still Phase 2 only. **04 / RESEARCH PEPTIDE FUNDAMENTALS** A triple-receptor agonist with the largest reported weight-loss figures of any incretin-class compound to date — and, as of this writing, no approval anywhere and no completed outcome trial. ## The short version Retatrutide is an investigational peptide drug, also known by its development code LY3437943, that activates three separate hormone receptors at once — GLP-1, GIP, and glucagon. Adding the glucagon receptor to the now-familiar GLP-1/GIP combination is the mechanistic novelty: it is proposed to add calorie-burning (energy expenditure) on top of appetite suppression, rather than relying on eating less alone. The headline number — roughly a quarter of body weight lost at the highest dose over 48 weeks in a Phase 2 obesity trial — is real and comes from a randomized, placebo-controlled study. What it is not is an approved drug's outcome: retatrutide remains in Phase 3 trials, unapproved by any regulator, and all of the efficacy and safety data available come from Phase 1 and Phase 2 work. Material sold as research-grade retatrutide outside a clinical trial is unregulated and its actual identity and purity cannot be verified. ## What it is Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone, chemically modified with a C20 fatty-diacid arm that promotes strong albumin binding and extends its circulating half-life, enabling once-weekly subcutaneous dosing in the trials conducted so far. It is described as a triple agonist because a single molecule engages three separate G-protein-coupled receptors: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. That engagement is not uniform across the three targets. Structural work using cryo-electron microscopy found retatrutide is roughly 8.9 times more potent than the body's own GIP at the GIP receptor, but weaker than the native hormones at the glucagon and GLP-1 receptors — about 0.3 and 0.4 times native potency, respectively [17]. In other words, retatrutide is not equally active at all three receptors; it is engineered to lean heavily on GIP receptor activation while engaging the other two more modestly. ## How it works Retatrutide inherits the appetite-suppressing, insulin-augmenting pharmacology common to GLP-1 and GIP receptor agonists — slowed gastric emptying, glucose-dependent insulin release, reduced hunger signaling in the brain — and adds a third element: controlled activation of the glucagon receptor. Glucagon is normally the hormone that raises blood sugar by triggering the liver to release stored glucose, which is why unmanaged glucagon signaling would work against a diabetes or weight-loss drug. In the context of the simultaneous insulin-boosting effect from the other two receptors, however, the proposed net effect of the glucagon component is increased energy expenditure — through brown-fat thermogenesis and fat-burning — with only a modest impact on blood glucose overall. The practical implication, according to a 2025 narrative review of the compound's trial program, is that retatrutide works on both sides of the energy-balance equation at once: the GLP-1/GIP arms reduce how much is eaten, and the glucagon arm is proposed to raise how much energy is burned [16]. That combined-mechanism hypothesis is plausible and consistent with the trial results reported so far, but the review itself frames it as a mechanistic account built on Phase 1/2 data rather than a fully resolved mechanism confirmed by dedicated human mechanistic studies. ## What the research shows *Phase 2 obesity trial — the headline number.* In 338 adults with obesity, once-weekly retatrutide at 12 mg produced a mean body-weight change of -24.2% over 48 weeks, versus -2.1% with placebo. Gastrointestinal adverse events were dose-related and mostly mild to moderate, and a dose-dependent increase in heart rate was observed, peaking around week 24 [19]. This is a single randomized, placebo-controlled Phase 2 trial — a real and rigorous study, but one trial, in one population, with a third of a thousand participants, not a confirmed Phase 3 finding. *Phase 2 type 2 diabetes trial.* In 281 adults with type 2 diabetes, retatrutide 12 mg lowered HbA1c by roughly 2 percentage points at 24 weeks and reduced body weight by nearly 17% at 36 weeks versus placebo, with mild-to-moderate GI adverse events in about a third of participants and no severe hypoglycemia or deaths reported [20]. A second, independent Phase 2 population, but again Phase 2. *Metabolic liver disease substudy.* In a 98-participant Phase 2 substudy of adults with obesity and metabolic liver disease, retatrutide 12 mg reduced liver fat by over 80% at 24 weeks, with the large majority of participants reaching normal liver fat levels [18]. Promising, but a substudy within the same early-phase program. *Structural pharmacology.* Cryo-EM work resolved how retatrutide physically engages all three of its target receptors, confirming the triple-agonist binding and the receptor-by-receptor potency differences described above [17]. This is molecular structural biology — it explains how the drug works, not how well it works in people, though it is a genuinely well-supported piece of the mechanism. *Synthesis review.* A 2025 narrative review pulls the above trials and the structural work together, characterizing the roughly 24% Phase 2 weight-loss figure as a meaningful step beyond prior incretin-class drugs, while explicitly noting that Phase 3 confirmation has not yet reported [16]. Every efficacy and safety number currently available for retatrutide sits inside this same Phase 1/2 evidence envelope — nothing here has cleared a Phase 3 bar yet. ## Reported effects, cautions & safety Community-reported experience with retatrutide is, like the other compounds on this desk, **anecdotal, not clinical evidence** — drawn from online forums and consumer-facing peptide sites, not from the trials cited above, and none of it tied to a verified dose or product. The most consistently described benefit is a near-total quieting of food-related thoughts, alongside rapid weight reduction that broadly tracks the trial trajectory. A distinct sensation of warmth or mild sweating is frequently attributed by users to the glucagon-receptor arm specifically, and some describe a modest mood lift. On the adverse side, an elevated resting heart rate — sometimes tracked on wearables as a 5-to-15 beats-per-minute increase — is a recurring theme that maps directly onto the dose-dependent heart-rate signal documented in the Phase 2 obesity trial [19]. Nausea in the hours after dosing, sulfur-smelling burps, fatigue, constipation, occasional injection-site irritation, and sleep disturbance round out the more common complaints. The cited safety concerns are grounded directly in the trial data rather than speculation. Retatrutide remains unapproved and investigational; material obtained outside a registered clinical trial cannot be verified for identity, purity, or sterility, and regulators issued enforcement actions against vendors of unapproved retatrutide in 2025 [16][19]. Gastrointestinal adverse events were the leading reason for trial discontinuation at the highest dose, with nausea documented in nearly half of participants at that level [19]. The dose-dependent heart-rate increase observed in Phase 2, peaking around week 24, has not yet been evaluated in a dedicated long-term cardiovascular outcomes trial, so its significance for someone with an existing arrhythmia is genuinely unknown [19]. Because retatrutide augments insulin secretion, combining it with insulin or a sulfonylurea carries a real hypoglycemia risk that trial protocols managed by adjusting background diabetes medication [20] — an adjustment that does not happen in unsupervised research use. Body-composition data show some reduction in lean mass alongside fat mass, and because retatrutide's pivotal outcome trials are still ongoing, its long-term safety profile remains an open question rather than a settled one. ## Where it fits in the evidence hierarchy Retatrutide has the single most impressive efficacy number on this desk — a quarter of body weight lost in a controlled Phase 2 trial [19] exceeds anything reported for [semaglutide](/semaglutide) at a comparable timepoint. But 'best Phase 2 number' and 'best-evidenced' are not the same claim, and this desk keeps them separate deliberately. Semaglutide's evidence base includes multiple large Phase 3 outcome trials across different populations and endpoints [21][22][23][24]; retatrutide's entire evidence base, however promising, is still Phase 2 [16][18][19][20]. Read against [CJC-1295](/cjc-1295), [ipamorelin](/ipamorelin), and [KPV](/kpv) — which have essentially no controlled human efficacy data at all — retatrutide looks impressively advanced. Read against semaglutide, it looks like a drug one clinical phase away from the evidence tier it is often marketed as already occupying. See the [comparison page](/compare) for the full picture. ![Retatrutide research illustration — abstract triple-receptor agonist motif in teal noir](/images/retatrutide.webp) --- A skeptic's literature desk — we say plainly when the evidence behind a claim is a single small trial, a rat model, or nothing but community anecdote, before we say anything else. --- # Semaglutide: The Compound the Other Four Are Implicitly Measured Against > Semaglutide: Research Overview — Best Peptide — A skeptic's literature summary of semaglutide, the FDA-approved GLP-1 receptor agonist. Covers mechanism, the large outcome-trial record, where it lost a head-to-head trial, and cited safety cautions. **05 / RESEARCH PEPTIDE FUNDAMENTALS — LEAD COMPOUND** The only peptide on this desk with a genuinely large, repeated, positive outcome-trial record across multiple populations — and even here, the evidence has real limits worth stating plainly. ## The short version Semaglutide is a lab-made version of a natural gut hormone, GLP-1, engineered to last about a week in the body instead of a couple of minutes. It is an FDA-approved prescription medicine, not a research chemical, used for type 2 diabetes, chronic weight management, reducing cardiovascular risk in people who already have heart disease, and — since 2025 — a form of fatty liver disease. It comes as a weekly injection or a daily pill. Of the five compounds on this desk, semaglutide has by a wide margin the largest and most rigorous evidence base: multiple randomized trials, some enrolling tens of thousands of participants, run specifically to test hard outcomes like heart attacks and kidney failure, not just weight on a scale. That is precisely why it is treated as the benchmark here rather than because it is somehow the most interesting compound scientifically. This page states its real trial results, and it also states plainly where semaglutide lost a head-to-head comparison and where its evidence has genuine gaps. It recommends no dose for any individual. ## What it is Semaglutide is a 31-amino-acid analog of human glucagon-like peptide-1 (GLP-1), sharing roughly 94% of its sequence with the natural hormone. Two changes give it its defining pharmacokinetic property: a substitution at position 8 blocks the enzyme (DPP-4) that normally destroys native GLP-1 within about two minutes, and a fatty-acid side chain attached at position 26 binds strongly and reversibly to serum albumin in the blood. That albumin binding shields the peptide from clearance and breakdown, producing a roughly week-long circulating presence that is the entire structural basis for once-weekly dosing. The oral tablet formulation is a separate engineering problem: it is co-formulated with an absorption enhancer that briefly raises stomach-surface pH long enough for a small fraction of the dose to be absorbed before acid degrades it. Oral bioavailability is low — under 1% of an oral tablet dose typically reaches circulation — which is why the oral form requires strict fasted dosing with minimal water and no other food or medication nearby. ## How it works Semaglutide activates GLP-1 receptors throughout the body. In the pancreas, it boosts insulin release only when blood sugar is already elevated (glucose-dependent), which limits the risk of dangerously low blood sugar when used alone, and it suppresses inappropriate glucagon release from the pancreas's alpha cells. It also slows gastric emptying, which blunts the post-meal blood-sugar spike and is part of why nausea is such a common early side effect. The weight-loss effect is understood to be primarily a brain effect rather than a gut effect: semaglutide reaches appetite-regulating circuits in the hypothalamus and brainstem, activating neurons that signal fullness and suppressing neurons that drive hunger, and it does this without measurably lowering the body's baseline energy expenditure — the weight comes off because less is eaten, not because more is burned [26]. Beyond glucose and appetite, GLP-1 receptors in the heart and kidneys appear to mediate separate protective effects that large outcome trials have now confirmed directly, rather than merely inferred from weight loss alone [22][23]. ## What the research shows *Head-to-head against a dual agonist — semaglutide's honest limitation.* In a 72-week, open-label trial of 751 adults with obesity, tirzepatide, a dual GIP/GLP-1 receptor agonist, produced significantly greater weight loss than semaglutide — 20.2% versus 13.7%, a roughly 6.5-percentage-point gap [21]. This is worth stating first, not last: semaglutide is the benchmark on this desk for its overall evidence base, not because it wins every comparison. *Weight management.* In 1,961 adults with overweight or obesity and no diabetes, once-weekly semaglutide produced a mean 14.9% body-weight reduction at 68 weeks versus 2.4% with placebo [24] — the trial that established the weight-management indication. *Cardiovascular outcomes.* In over 17,600 adults with existing cardiovascular disease and overweight or obesity but no diabetes, semaglutide reduced the combined rate of cardiovascular death, heart attack, or stroke by 20% relative to placebo [23] — a genuine hard-outcome trial, not a surrogate weight or glucose endpoint. *Kidney outcomes.* In 3,533 adults with type 2 diabetes and chronic kidney disease, semaglutide reduced the risk of major kidney-disease events by 24% versus placebo [22] — another hard-outcome trial in a population selected specifically to test it. *Earlier cardiovascular trial, with a caveat.* In an earlier trial of 3,297 adults with type 2 diabetes at cardiovascular risk, semaglutide reduced cardiovascular events, but retinopathy complications occurred significantly more often in the semaglutide group — a signal thought to reflect harm from rapid blood-sugar correction in people who already had retinopathy, rather than a direct toxic effect [27]. *Mechanism, not outcome.* Rodent studies mapped exactly where in the brain semaglutide acts to reduce food intake, without reducing energy expenditure [26] — useful mechanistic grounding, but an animal study, included here because it explains the human trial results above rather than adding a new efficacy claim. *Dedicated safety review.* An independent safety review concludes semaglutide's overall risk-benefit balance is favorable in type 2 diabetes, with gastrointestinal effects as the dominant, mostly transient adverse-effect category, alongside a real (if weight-loss-attributable) increase in gallbladder disease risk, and pancreatic- and thyroid-cancer signals it explicitly says are too rare to draw firm conclusions from either way [25]. ## Reported effects, cautions & safety Community-reported experience with semaglutide is widespread, given how long it has been on the market, but it remains **anecdotal, not clinical evidence** — self-reported, unverified, and separate from the trial data above. The most consistently described benefit is a quieting of persistent food-related thoughts within the first one to two weeks, alongside sharply reduced cravings for sugar and fried food. Most reviewers describe steady weight loss over months, and people using semaglutide for diabetes commonly report meaningfully improved blood-sugar readings. A widely discussed secondary effect is reduced interest in alcohol. On the adverse side, nausea is the single most reported complaint, described by roughly a third of reviewers and typically worst in the first weeks and after dose increases [25]. Distinctive sulfur-smelling burps, alternating constipation and diarrhea, acid reflux, early fatigue on injection day, and occasional headaches are also frequently described, along with food aversions and, less often, hair shedding tied to rapid weight loss rather than to a direct drug effect. The clinically documented cautions are more specific than the anecdotal ones. Gastrointestinal intolerance during dose escalation is the leading adverse effect and the primary reason people discontinue [25]. Semaglutide carries a boxed warning for thyroid C-cell tumors based on rodent data, making a personal or family history of medullary thyroid carcinoma or MEN-2 a contraindication, even though the human signal itself remains unconfirmed [25]. Acute pancreatitis is a class warning, again without a confirmed quantitative risk increase in humans [25]. Gallbladder and biliary disease risk is a real, if largely weight-loss-attributable, finding [25]. In people with pre-existing diabetic retinopathy, rapid blood-sugar correction on semaglutide was linked to significantly more retinopathy complications in a dedicated trial [27][25]. Body-composition substudies show a meaningful share of lost weight is lean muscle, raising a sarcopenia concern for older adults, and extension data show substantial weight regain after stopping, which is why it is framed as a chronic rather than curative therapy. The oral tablet's low bioavailability means it must be taken fasted, with minimal water nearby, or its effective dose drops considerably. **Clinical boundary** ## Evidence does not replace screening **Prescription access** ![Promise Peptides Semaglutide product card marked Rx only](https://mypromise.com/media/products/semaglutide.png) *Promise Peptides product image (mypromise.com). The Semaglutide card displays an Rx only marking.* For a compound with this much outcome data and this many contraindications, the dividing line is not reader confidence but clinical screening: Semaglutide belongs in prescription-only care through a licensed clinician-led service, of which Promise Peptides (mypromise.com) is one example. ## Where it fits in the evidence hierarchy Semaglutide is the lead compound on this desk because its evidence base is categorically different from the other four: repeated, large, randomized, hard-outcome trials across multiple distinct populations and endpoints [21][22][23][24][27], not a single pharmacokinetic study or one trial that missed its mark. That said, being the best-evidenced compound here is not the same as being unbeatable or without limits — [retatrutide](/retatrutide) already outperforms it on raw Phase 2 weight-loss numbers [19], and semaglutide lost its own head-to-head trial against tirzepatide [21]. Compared with [CJC-1295](/cjc-1295), [ipamorelin](/ipamorelin), and [KPV](/kpv) — none of which has a completed human efficacy trial supporting its marketed uses — the gap is not close. Semaglutide earns the lead position on this desk on the strength of its trial record, not on the strength of its marketing. See the [comparison page](/compare) for the full evidence-maturity comparison across all five. ![Semaglutide research illustration — abstract single-receptor incretin motif in teal noir](/images/semaglutide.webp) --- A skeptic's literature desk — we say plainly when the evidence behind a claim is a single small trial, a rat model, or nothing but community anecdote, before we say anything else. --- # Five Compounds, Ranked by What Their Evidence Actually Supports > Compare CJC-1295, Ipamorelin, KPV, Retatrutide, and Semaglutide — Best Peptide — A side-by-side evidence-maturity comparison of five Research Peptide Fundamentals research peptides — mechanism, most-studied application, trial depth, regulatory status, and the single biggest caution for each. **RESEARCH PEPTIDE FUNDAMENTALS / EVIDENCE MATRIX** Mechanism, most-studied application, evidence maturity, regulatory status, and the single biggest caution for each — read side by side rather than compound by compound. ## The short version This page lines up [CJC-1295](/cjc-1295), [ipamorelin](/ipamorelin), [KPV](/kpv), [retatrutide](/retatrutide), and [semaglutide](/semaglutide) on the dimensions that actually determine how much confidence a reader should place in a claim: what receptor or pathway each one targets, what it has been most studied for, how mature that evidence really is (rodent-only, single human trial, or repeated large trials), how it has been administered in the studies that exist, its regulatory status, and the one caution most worth remembering about each. The short version of the long version below: evidence maturity does not track neatly with how often a compound is discussed in research-peptide communities. KPV, the least discussed of the five in mainstream weight-loss circles, has the cleanest mechanistic story; semaglutide, the most discussed and most heavily marketed, also happens to have, by a wide margin, the strongest human trial record. None of this is medical advice, and no dose is recommended anywhere on this page. ## The comparison matrix | Dimension | CJC-1295 | Ipamorelin | KPV | Retatrutide | Semaglutide | | --- | --- | --- | --- | --- | --- | | Target / class | GHRH receptor agonist (GH secretagogue) | Ghrelin receptor (GHS-R1a) agonist | Melanocortin-derived anti-inflammatory tripeptide | GIP/GLP-1/glucagon triple receptor agonist | GLP-1 receptor agonist | | Most studied for | GH/IGF-1 elevation pharmacokinetics | Postoperative gut motility; GH release | Intestinal (colitis) inflammation | Obesity, type 2 diabetes, metabolic liver disease | Type 2 diabetes, obesity, cardiovascular & kidney outcomes | | Human efficacy trials | None | One RCT — missed primary endpoint [8] | None published | Phase 2 only, ongoing Phase 3 [19][20] | Multiple large Phase 3 outcome trials [21][22][23][24] | | Deepest evidence | Small human PK/pharmacology studies [3][4][5] | Human PK study + one RCT [8][9] | Mouse colitis models, in vitro mechanism [11][13][14] | Phase 2 RCTs, ~280-340 participants each [19][20] | Phase 3 RCTs, hundreds to 17,000+ participants [21][23][24] | | Regulatory status | Not approved anywhere; research chemical | Not approved anywhere; research chemical | Not approved anywhere; research chemical | Investigational; not approved anywhere as of 2026 | FDA-approved (multiple indications) | | Biggest single caution | No efficacy trial has ever tested its marketed uses | Its only human trial did not meet its goal | No human trial exists at all | Unapproved, unverified gray-market supply; dose-dependent heart-rate signal [19] | Even the best-evidenced compound here lost its own head-to-head trial [21] | ## Target and mechanism The five compounds sit on genuinely different biological pathways, which is part of why lumping them together as 'research peptides' obscures more than it clarifies. CJC-1295 and ipamorelin both aim at growth-hormone release, but through different receptors — GHRH receptor and ghrelin receptor, respectively — which is the stated rationale for using them together, though that combination itself has never been trial-tested. KPV works through an entirely separate anti-inflammatory pathway centered on NF-kB and MAP-kinase suppression, delivered via a gut transporter rather than a classical hormone receptor [13]. Retatrutide and semaglutide both work through incretin biology, with retatrutide adding two additional receptor targets (GIP and glucagon) on top of the single GLP-1 target semaglutide occupies [17]. ## Evidence maturity — the dimension that matters most This is where the five genuinely separate, and it is the organizing question of this entire desk. Semaglutide sits at the top: a decade-plus of large, randomized, hard-outcome trials across diabetes, obesity, cardiovascular disease, and kidney disease [21][22][23][24]. Retatrutide is one tier below — real randomized Phase 2 trials with a few hundred participants each, promising numbers, but no completed Phase 3 [19][20]. Ipamorelin has exactly one human randomized trial, and it missed its primary endpoint [8]. CJC-1295 has small human pharmacokinetic studies but zero controlled efficacy trials of any kind [4][5]. KPV has the most internally consistent mechanistic story of the five — replicated across independent studies and multiple mouse models [11][13][14] — and also the least human evidence: none. A reader who only skims marketing copy would likely rank these five in something close to the reverse order of their actual evidence maturity. ## Regulatory and administration status Semaglutide is the only FDA-approved compound on this desk, available as a prescription weekly injection or daily tablet. Retatrutide is investigational, administered by subcutaneous injection in its Phase 2/3 trials, with no approval anywhere. CJC-1295, ipamorelin, and KPV are, by regulatory status, research chemicals with no approved human indication in any jurisdiction; the human studies that exist for CJC-1295 and ipamorelin used clinical-research dosing under supervision, not the unsupervised subcutaneous protocols common in research-use communities today. ## The single biggest caution for each For **CJC-1295**, it is simply that no efficacy trial exists for any of its marketed uses — the pharmacology is real, the outcomes are untested. For **ipamorelin**, it is that its one human efficacy trial did not meet its own primary endpoint [8], a fact that gets lost in most marketing. For **KPV**, it is the complete absence of human trial data of any kind — a promising rodent mechanism is not the same claim as a demonstrated human effect. For **retatrutide**, it is unapproved and unverified gray-market supply combined with a documented dose-dependent heart-rate signal that has not been evaluated in a long-term cardiovascular trial [19]. For **semaglutide**, even at the top of this evidence hierarchy, it is that the drug lost its own head-to-head trial against tirzepatide [21] — a reminder that 'best-evidenced' is a statement about trial rigor, not a claim of superiority on every metric. --- A skeptic's literature desk — we say plainly when the evidence behind a claim is a single small trial, a rat model, or nothing but community anecdote, before we say anything else. --- # Direct Answers, Graded by Evidence > Research Peptide FAQ — CJC-1295, Ipamorelin, KPV, Retatrutide, Semaglutide — Best Peptide — Direct, evidence-graded answers to the questions readers most often bring to CJC-1295, ipamorelin, KPV, retatrutide, and semaglutide, with citations to the primary and review literature. **RESEARCH PEPTIDE FUNDAMENTALS / FAQ** The questions readers most often bring to CJC-1295, ipamorelin, KPV, retatrutide, and semaglutide, answered against the actual published record. ## What is CJC-1295? CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), chemically modified to resist enzymatic breakdown and, in its long-acting DAC form, to bind circulating albumin so a single dose keeps growth hormone and IGF-1 elevated for days rather than minutes [4]. It is not approved for human use anywhere and is sold only as a research chemical. ## Is CJC-1295 safe? No dedicated human safety trial of CJC-1295 exists, so 'safe' cannot be answered with clinical-trial confidence either way. What is documented is that growth-hormone-axis stimulation carries known, mechanism-based cautions — theoretical cancer risk via IGF-1 elevation, fluid retention, and effects on insulin sensitivity — alongside a discontinued original development program and an FDA-flagged immunogenicity concern for long-acting GHRH analogs as a class [1]. The honest answer is that CJC-1295's safety, at the doses and durations used in research-community protocols, has simply not been tested in a controlled human trial. ## What is ipamorelin? Ipamorelin is a five-amino-acid peptide that selectively activates the ghrelin receptor (GHS-R1a) on the pituitary gland, triggering growth-hormone release without meaningfully raising cortisol or prolactin — its defining pharmacological feature relative to older growth-hormone-releasing peptides. It has never been approved as a drug; its only human efficacy trial, testing it for postoperative gut recovery, did not meet its primary endpoint [8]. ## What are the risks of ipamorelin? The documented risks are mechanistic rather than drawn from a dedicated long-term ipamorelin safety trial, because none exists. Growth-hormone elevation carries a theoretical cancer-risk concern via IGF-1. A structurally related (not identical) ghrelin-receptor agonist produced dose-dependent heart muscle damage in a 28-day rat study, which keeps chronic cardiovascular safety an open question for this receptor class [7]. Ipamorelin's own direct effect on pancreatic insulin release in animal tissue, combined with growth hormone's glucose-sparing action, makes its net effect on blood sugar difficult to predict in anyone with diabetes or insulin resistance. ## What is KPV peptide used for? In published research, KPV has been studied exclusively for reducing intestinal inflammation in mouse models of colitis, where it consistently lowers inflammatory cytokines and speeds recovery [11][13][14]. It has never been tested in a human clinical trial for this or any other use, so 'used for' should be read as 'studied for in animals,' not as an established human application. ## What does retatrutide do? Retatrutide activates three receptors at once — GLP-1, GIP, and glucagon — combining appetite suppression with a proposed increase in energy expenditure from the glucagon-receptor component. In a Phase 2 obesity trial, the highest dose produced roughly 24% mean body-weight loss over 48 weeks versus about 2% with placebo [19]. It remains investigational and unapproved by any regulator. ## Is retatrutide FDA approved? No. As of this writing, retatrutide has not been approved by the FDA or any other regulatory agency; it is in Phase 3 clinical trials. All efficacy and safety data currently available come from Phase 1 and Phase 2 studies, and material sold outside those trials as research-grade retatrutide cannot be verified for identity or purity [16][19]. ## What is semaglutide? Semaglutide is a GLP-1 receptor agonist — an engineered analog of a natural gut hormone — approved by the FDA for type 2 diabetes, chronic weight management, reducing cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and, since 2025, a form of fatty liver disease. It is the only compound on this desk that is a prescription medicine rather than a research chemical. ## What is semaglutide used for? Its approved uses are lowering blood glucose in type 2 diabetes, reducing body weight in chronic weight management, reducing the risk of major cardiovascular events in people with established cardiovascular disease and overweight or obesity [23], and treating metabolic dysfunction-associated steatohepatitis. It has also reduced major kidney-disease events in people with type 2 diabetes and chronic kidney disease in a dedicated outcomes trial [22]. ## How does semaglutide work for weight loss? Semaglutide reaches appetite-regulating circuits in the hypothalamus and brainstem, activating neurons that signal fullness and suppressing neurons that drive hunger, without measurably lowering the body's baseline energy expenditure [26]. In its largest weight-management trial, that translated into a mean 14.9% body-weight reduction over 68 weeks versus 2.4% with placebo [24] — though in a later head-to-head trial, tirzepatide outperformed it [21]. ## How much CJC-1295 should I take? This desk does not answer that question, and no page here will. CJC-1295 is not an approved drug, no clinical dosing guideline exists for it, and there is no controlled human efficacy trial establishing what any dose actually accomplishes. The human pharmacokinetic studies that do exist used specific research doses — 30 to 90 micrograms per kilogram — under clinical supervision to measure hormone levels, not to establish a safe or effective dose for self-administration [4][5]. A dosing question about an unapproved research chemical is a question for a qualified physician or toxicologist, not a website. ## How to reconstitute retatrutide? This desk does not provide reconstitution, handling, or administration instructions for any compound, and retatrutide is not approved for use outside registered clinical trials in the first place. Retatrutide obtained through research-chemical channels is not manufactured, tested, or verified to pharmaceutical standards, and there is no regulator-reviewed guidance for handling it outside a trial protocol. Questions about administering an investigational drug belong with the clinical trial sponsoring it, not with an independent literature digest. --- A skeptic's literature desk — we say plainly when the evidence behind a claim is a single small trial, a rat model, or nothing but community anecdote, before we say anything else. --- # About This Scorecard > About Best Peptide — An Evidence-Graded Scorecard — About Best Peptide: an independent literature digest that grades five research peptides by the strength of their evidence rather than by how they are marketed. Not a seller, not a clinic, not medical advice. **RESEARCH PEPTIDE FUNDAMENTALS / COLOPHON** A literature scorecard built on one discipline: say what the evidence actually supports, and say plainly when it doesn't support much yet. ## What the scorecard covers Best Peptide grades the evidence behind five research peptides that are often discussed together but sit at very different points on the evidence ladder: CJC-1295, ipamorelin, KPV, retatrutide, and semaglutide, with semaglutide as the lead compound on the strength of its trial record. The scorecard exists because research-peptide marketing routinely treats 'published research exists' as if it meant 'this works and is safe,' when a single eleven-person pharmacokinetic study and a 17,000-participant randomized outcome trial are not remotely the same kind of evidence, even though both technically count as published research. The organizing idea is to grade evidence honestly across categories that rarely get compared side by side: a growth-hormone-releasing-hormone analog, a ghrelin-receptor secretagogue, an anti-inflammatory tripeptide, an investigational metabolic triple-agonist, and one fully approved metabolic drug. Read together, the differences in evidence maturity are far harder to miss than they are in any single compound's marketing. ## How the scorecard is kept Three habits govern the site. First, every factual claim ties to a specific citation on the [references page](/references) — peer-reviewed journal articles and clinical-trial publications, with DOIs and PubMed links — and each compound page separates primary research from review-level synthesis. Second, findings are reported in the species and population actually studied: a rat pharmacology result is labeled a rat result; an eleven-person study is labeled small; a Phase 2 trial is labeled Phase 2, not quietly upgraded to proven. Third, where the published record is thin or absent in humans — as with KPV — the scorecard says so directly rather than filling the gap with confident-sounding mechanism talk borrowed from animal data. Community-reported experience appears where it exists, because it is genuinely part of how these compounds are discussed, but every such paragraph is marked as anecdotal and unverified, and none is presented as though it came from a controlled trial. ## The boundaries Best Peptide is not a pharmacy, clinic, telehealth service, or seller of any kind. It sells, sources, and brokers no compound, and it holds no affiliate or referral tie to any research-chemical supplier or pharmaceutical company. It does not diagnose, prescribe, or name a dose, schedule, or route for any person, for any of the five compounds covered here. Semaglutide is an approved prescription medicine available only through licensed medical providers. Retatrutide is investigational and not legally available outside registered clinical trials. CJC-1295, ipamorelin, and KPV are, by regulatory status, research chemicals with no approved human indication anywhere; nothing here should be read as encouragement to obtain or use any of them outside a legitimate research or clinical context. A reader seeking medical guidance should consult a licensed clinician. Editorial correspondence on citations, corrections, or newly published research can go to the [contact page](/contact). --- A skeptic's literature desk — we say plainly when the evidence behind a claim is a single small trial, a rat model, or nothing but community anecdote, before we say anything else. --- # Contact the Editorial Desk > Contact Best Peptide — Editorial Desk — Reach the Best Peptide editorial desk regarding citations, corrections, or research-related correspondence about the CJC-1295, ipamorelin, KPV, retatrutide, and semaglutide literature digest. **RESEARCH PEPTIDE FUNDAMENTALS / COLOPHON** Correspondence on citations, corrections, and newly published research — exactly what a skeptic's scorecard exists to receive. ## Correspondence Best Peptide is glad to hear about the research record itself: a citation quoted inaccurately, a clinical trial that has published new results, a regulatory status update, or a peer-reviewed study on CJC-1295, ipamorelin, KPV, retatrutide, or semaglutide that belongs on the [references page](/references). Corrections that improve the accuracy or currency of the scorecard are the most useful messages it receives. The most actionable submissions name the page in question, the exact passage being challenged, and a supporting reference — a DOI or PubMed identifier where possible — so the proposed change can be checked against its source before anything is revised. **Editorial mailbox:** editors@bestpeptide.org ## What the scorecard cannot do Best Peptide is a graded reading of literature, not a clinical service or a seller, so it cannot advise on or recommend human use of any peptide covered here, suggest a dose or schedule for any individual, judge whether a cited finding applies to a specific person's situation, or help locate, source, or purchase any compound from any supplier. It cannot guide anyone toward prescription medicine outside a licensed prescriber relationship, and it cannot advise athletes on anti-doping status for any compound. Semaglutide is available only by prescription. Retatrutide is investigational and not legally available outside clinical trials. CJC-1295, ipamorelin, and KPV are unapproved research chemicals. A reader seeking clinical guidance should consult a licensed healthcare provider. Replies to correspondence are not guaranteed and may lag. --- A skeptic's literature desk — we say plainly when the evidence behind a claim is a single small trial, a rat model, or nothing but community anecdote, before we say anything else. --- # References > References — Research Peptide Fundamentals Literature — Best Peptide — The aggregated citation list for the Best Peptide research-fundamentals digest: peer-reviewed sources on CJC-1295, ipamorelin, KPV, retatrutide, and semaglutide, with DOIs and PubMed links. **RESEARCH PEPTIDE FUNDAMENTALS / REFS** Every source cited across the five compound pages and the comparison, gathered in one place. ## References The list below aggregates every citation used across the five peptide pages and the comparison page on this desk — CJC-1295, ipamorelin, KPV, retatrutide, and semaglutide. Each entry lists authors, title, journal, and year, with a DOI and PubMed or PubMed Central link where one exists. A source is listed once and referenced by its number throughout the site. Reviews and other secondary syntheses are cited as such rather than presented as primary trial data. ## References [1] Granata R, Leone S, Zhang X, Gesmundo I, et al. Growth hormone-releasing hormone and its analogues in health and disease. Nat Rev Endocrinol. 2025;21(3):180-195. https://pubmed.ncbi.nlm.nih.gov/39537825/ [2] Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Test Anal. 2010;2(11-12):647-650. https://doi.org/10.1002/dta.233 [3] Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. https://pubmed.ncbi.nlm.nih.gov/19386527/ [4] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/ [5] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/ [6] Lu Z, Ngan MP, Liu JYH, Yang L, Tu L, Chan SW, Giuliano C, Lovati E, Pietra C, Rudd JA. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiology & Behavior. 2024;284:114644. https://pubmed.ncbi.nlm.nih.gov/39043357/ [7] Stokes AH, Falls JG, Yoon L, Cariello N, Faiola B, Colton HM, Jordan HL, Berridge BR. Integrated approach to early detection of cardiovascular toxicity induced by a ghrelin receptor agonist. International Journal of Toxicology. 2015;34(2):151-161. https://pubmed.ncbi.nlm.nih.gov/25722321/ [8] Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease. 2014;29(12):1527-1534. https://pubmed.ncbi.nlm.nih.gov/25331030/ [9] Gobburu JV, Agerso H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research. 1999;16(9):1412-1416. https://pubmed.ncbi.nlm.nih.gov/10496658/ [10] Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Hormone & IGF Research. 1999;9(2):106-113. https://pubmed.ncbi.nlm.nih.gov/10373343/ [11] Zhang D, et al. PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combination treatment of acute and chronic DSS-induced colitis. Front Pharmacol. 2024;15:1442876. https://pubmed.ncbi.nlm.nih.gov/39211778/ [12] Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017;25(7):1628-1640. https://pubmed.ncbi.nlm.nih.gov/28143741/ [13] Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. https://pubmed.ncbi.nlm.nih.gov/18061177/ [14] Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. https://pubmed.ncbi.nlm.nih.gov/18092346/ [15] Brzoska T, Luger TA, Maaser C, Abels C, Bohm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocr Rev. 2008;29(5):581-602. https://pubmed.ncbi.nlm.nih.gov/18612139/ [16] Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15:796. https://pmc.ncbi.nlm.nih.gov/articles/PMC12190491/ [17] Li W, Zhou Q, Cong Z, Yuan Q, Li W, Zhao F, Xu HE, Zhao LH, Yang D, Wang MW. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery. 2024;10:77. https://pmc.ncbi.nlm.nih.gov/articles/PMC11255275/ [18] Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine. 2024;30:2037-2048. https://pmc.ncbi.nlm.nih.gov/articles/PMC11271400/ [19] Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/ [20] Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544. https://pubmed.ncbi.nlm.nih.gov/37385280/ [21] Aronne LJ, et al. (SURMOUNT-5 Investigators). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. https://pubmed.ncbi.nlm.nih.gov/40353578/ [22] Perkovic V, et al. (FLOW Trial Committees and Investigators). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. https://pubmed.ncbi.nlm.nih.gov/38785209/ [23] Lincoff AM, et al. (SELECT Trial Investigators). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. https://pubmed.ncbi.nlm.nih.gov/37952131/ [24] Wilding JPH, et al. (STEP 1 Study Group). Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/ [25] Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021. https://pubmed.ncbi.nlm.nih.gov/34305810/ [26] Gabery S, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020. https://pubmed.ncbi.nlm.nih.gov/32213703/ [27] Marso SP, et al. (SUSTAIN-6 Investigators). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016. https://pubmed.ncbi.nlm.nih.gov/27633186/ --- A skeptic's literature desk — we say plainly when the evidence behind a claim is a single small trial, a rat model, or nothing but community anecdote, before we say anything else.